Clinical implication of anti-angiogenic effect of regorafenib in metastatic colorectal cancer

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Lim, Yoojoo ^a   Han, Sae Won ^a,b   Yoon, Jeong Hee ^a   Lee, Jeong Min ^a   Lee, Jung Min ^a   Paeng, Jin Chul ^a   Won, Jae Kyung ^a   Kan, Gyeong Hoon ^a   Jeong, Seung Yong ^a   Park, Kyu Joo ^a   Lee, Kyung Hun ^a   Kim, Jee Hyun ^c   Kim, Tae You ^a,b,d  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; REGORAFENIB; ANGIOGENESIS INHIBITOR; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CONTROL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; IMAGE ANALYSIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PET SCANNER; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; METASTASIS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR VOLUME; VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PHENYLUREA COMPOUNDS; PYRIDINES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84956617370     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145004     Document Type: Article

References (24)

1. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011; 129(1):245-255. doi: 10.1002/ijc.25864 PMID: 21170960.
2. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863):303-312. doi: 10.1016/S0140-6736 (12)61900-X PMID: 23177514.
3. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381 (9863):295-302. doi: 10.1016/S0140-6736(12)61857-1 PMID: 23177515.
4. Li J, Qin S, Yau T, Ma B, Pan H, Xu J, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015; 16(6):619-629. doi: 10.1016/S1470-2045(15)70156-7 PMID: 25981818.
5. Jeffers M, Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, et al. Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. ASCO Meeting Abstracts. 2013; 31(4-suppl):381.
6. Lenz H-J, Van Cutsem E, Sobrero AF, Siena S, Falcone A, Ychou M, et al. Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer. ASCO Meeting Abstracts. 2013; 31(15-suppl):3514.
7. Abou-Elkacem L, Arns S, Brix G, Gremse F, Zopf D, Kiessling F, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013; 12(7):1322-1331. doi: 10.1158/1535-7163.MCT-12-1162 PMID: 23619301.
8. Cyran CC, Kazmierczak PM, Hirner H, Moser M, Ingrisch M, Havla L, et al. Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation. PLoS One. 2013; 8(9):e76009. doi: 10.1371/journal.pone. 0076009 PMID: 24098755.
9. Schmieder R, Hoffmann J, Becker M, Bhargava A, Muller T, Kahmann N, et al. Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int J Cancer. 2014; 135(6):1487-1496. doi: 10.1002/ijc.28669 PMID: 24347491.
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2):228-247. Epub 2008/12/23. doi: 10.1016/j.ejca.2008.10.026 PMID: 19097774.
11. O'Connor JP, Jayson GC. Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? Clin Cancer Res. 2012; 18(24):6588-6598. doi: 10.1158/1078-0432.CCR-12-1501 PMID: 23092875.
12. Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol. 2008; 3(4):351-357. doi: 10.1097/JTO.0b013e318168c7e9 PMID: 18379352.
13. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol. 2009; 27(3):404-410. doi: 10.1200/JCO.2008.16.2545 PMID: 19047292.
14. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Buchert M, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: A phase I study. Br J Cancer. 2012; 106(11):1722-1727. doi: 10. 1038/bjc.2012.153 PMID: 22568966.
15. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009; 302(21):2338-2344. doi: 10.1001/jama.2009.1755 PMID: 19952320.
16. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25(13):1753-1759. PMID: 17470865.
17. Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, et al. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. Eur J Cancer. 2014; 50(5):981-986. doi: 10.1016/j.ejca.2013.11.037 PMID: 24388774.
18. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. doi: 10.1055/s-0030-1247132 PMID: 20175033.
19. Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012; 118(1):147-156. doi: 10.1002/cncr.26255 PMID: 21713764.
20. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010; 194(1):157-165. doi: 10.2214/AJR.09.2941 PMID: 20028918.
21. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010; 194(6):1470-1478. doi: 10.2214/AJR.09.3456 PMID: 20489085.
22. Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, et al. Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging. 2012; 12:225-235. doi: 10.1102/1470-7330.2012.0027 PMID: 22743083.
23. Ricotta R, Sartore-Bianchi A, Verrioli A, Vanzulli A, Siena S. Regorafenib for metastatic colorectal cancer. Lancet. 2013; 381(9877):1537.
24. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol. 2013; 14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1 PMID: 23168366.